The Market Reports

Synopsis

The global market for Continuous Glucose Monitoring Systems was estimated to be worth US$ 12256 million in 2024 and is forecast to a readjusted size of US$ 31463 million by 2031 with a CAGR of 14.1% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Continuous Glucose Monitoring Systems cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Continuous Glucose Monitoring Systems (CGM) are advanced medical devices designed to continuously track glucose levels in the interstitial fluid of diabetic patients. The system typically consists of a small sensor inserted under the skin, which transmits glucose readings wirelessly to a receiver, smartphone, or insulin pump. Unlike traditional fingerstick testing, CGM offers real-time glucose trends, alerts for hypo- or hyperglycemia, and comprehensive data for personalized diabetes management. As sensor technology, wireless communication, and AI integration advance, CGM is increasingly positioned not only for diabetes care but also as a core component in broader digital health, sports medicine, and preventive care systems. In 2024, global Continuous Glucose Monitoring Systems production reached approximately 289057 k units, with an average global market price of around US$ 42.4/unit.

With the global diabetes population continuously expanding, CGM systems are gaining widespread adoption as effective tools for precise and intelligent glucose monitoring. In developed markets like the U.S. and Europe, expanding insurance reimbursement policies are significantly boosting CGM penetration among both Type 1 and Type 2 diabetes patients. Meanwhile, developing countries such as China and India, facing surging diabetes incidence, are experiencing rapid CGM market growth supported by digital healthcare reform and public health initiatives. Leading companies including Dexcom, Abbott, and Medtronic continue to innovate through features like calibration-free sensors, improved wearability, and seamless AI integration, driving user adherence and expanding clinical applications. Despite the strong market outlook, several barriers remain. High device costs pose affordability issues, particularly in markets without sufficient insurance coverage. Additionally, stringent requirements on accuracy, safety, and reliability increase R&D and manufacturing costs. Concerns around data privacy, system interoperability, and patient adoption persist, especially in regions where CGM’s clinical value is still under debate. Limited insurance reimbursement in some markets further restrains uptake. The market is also highly consolidated, dominated by a few global players with significant patent and brand advantages, creating high entry barriers for new competitors. There is a growing shift from hospital-centered care to patient-centric chronic disease management, driving demand for CGM systems in home settings and personal health applications. Home monitoring, telemedicine, and chronic care platforms are pushing CGM devices to integrate more deeply with mobile apps, wearables, and AI-based health services. New user groups such as fitness enthusiasts and women with gestational diabetes are emerging. Companies are evolving from traditional device suppliers into digital health ecosystem providers, building closed-loop solutions that combine hardware, platforms, and data analytics, and positioning CGM as a central component of proactive health management.

This report aims to provide a comprehensive presentation of the global market for Continuous Glucose Monitoring Systems, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Continuous Glucose Monitoring Systems by region & country, by Type, and by End Users.

The Continuous Glucose Monitoring Systems market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Continuous Glucose Monitoring Systems.

Market Segmentation

By Company

• Abbott
• DexCom
• Medtronic
• Senseonics Holdings
• Cnoga Medical
• Meiqi Medical
• Medtrum Technologies
• MicroTech Medical
• POCTech
• SIBIONICS
• GHA Life
• Infinovo Medical

Segment by Type

• Wearable
• Non-wearable

Segment by End Users

• Hospital
• Home Care
• Other

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.